Growth Catalysts

• DT-216P2 new drug product with corrected PK profile vs prior DT-216 (aims to sustain tissue exposure that matches target EC90 levels)
• FDA reviewed FECD data resulting in an IND clearance and plan to initiate DT-168 Phase 1 in 2024
• Plan for FECD observational study to de-risk endpoint selection before interventional trial
• Advancement of HD and DM1 programs based on allele-selective repeat biology and selected preclinical pharmacodynamic activity

Business Development

Financial Highlights

• Ended 2023 with approximately $281 million in cash, stated to provide an operating cash runway for the next five years
• No explicit Q4/FY financial guidance, revenue, or EPS figures were provided in the transcript excerpt

Capital Funding

• Cash balance: ~$281 million (end of 2023)
• Stated runway: five years; management claims it supports generating clinical proof-of-concept data in up to four programs (subject to R&D results/strategic review)

Strategy & Ops

• DT-216 pathway reset: move from prior formulation limitations to DT-216P2 with revised excipient to resolve injection site tolerability and extend exposure
• DT-216 clinical sequencing: Phase 1 PK study in healthy volunteers first; patient studies planned to begin in 2025
• FECD clinical sequencing: observational study prior to interventional drug trial to refine endpoints/patient characteristics
• HD/DM1 next milestones: choose development candidate(s) (HD) / declare development candidate (DM1), after further testing

Market Outlook

• Management stated Skyclarys approval (for Friedreich Ataxia) is not expected to materially reduce DT-216’s potential opportunity because it does not affect frataxin levels
• No explicit quantitative market or revenue guidance provided

Risks & Headwinds

• DT-216 prior formulation hurdle: transient exposure in plasma and tissue; tissue levels ~8–10 nM at day 2 and ~1 nM by day 7 (human muscle biopsies), which limited the duration of frataxin expression
• DT-216 prior tolerability hurdle: injection site thrombophlebitis events attributed to formulation excipients, which limited dosing frequency/levels
• Translational/endpoint risk highlighted indirectly by FDA-accelerated-approval question: management did not commit to accelerated approval paths or specific FDA endpoint requirements; they emphasized continuing engagement with FDA
• Fuchs observational study endpoint-definition risk: contrast/visual function endpoints (including progression measurement) may be challenging; management planned multiple endpoint buckets (visual quality, anterior eye tomography for edema, and corneal endothelium visualization) to address this
• Assay/biomarker measurement risk: continued need to reliably measure frataxin protein vs established RNA assays; management said they have robust RNA assays and are improving protein detection with updates as they progress to clinic